Literature DB >> 27422327

Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system.

Sujeong Yang1, Wei-Li Kuan1, Maria Grazia Spillantini2,3.   

Abstract

Multiple neurodegenerative disorders with tau pathology are characterised by the loss of memory and cognitive decline that can be associated with other symptoms including olfactory alterations that are often regarded as an early symptom of the diseases. Here, we have investigated whether olfactory dysfunction is present in the P301S human tau transgenic mice and if it is associated to tau pathology. Progressive tauopathy and neurodegeneration were noticeable in the olfactory bulb and piriform cortex at early age in the P301S human tau transgenic mice and olfactory sensitivity for social or non-social odours was significantly impaired at 3 months of age, when the piriform cortex-dependent odour-cross habituation was also disrupted. The olfactory alterations in the P301S tau transgenic mouse line provide an in vivo system where to test the mechanism-based therapies for the common and yet untreatable tauopathies.
© 2016 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  odour-cross habituation test; olfactory bulb; olfactory sensitivity; piriform cortex

Mesh:

Substances:

Year:  2016        PMID: 27422327     DOI: 10.1111/ejn.13333

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

Review 1.  Olfactory Evaluation in Alzheimer's Disease Model Mice.

Authors:  Jingjing Zhang; Zixuan Zhao; Siqi Sun; Jing Li; Yu Wang; Jingyin Dong; Su Yang; Yiyi Lou; Jing Yang; Weiyun Li; Shanshan Li
Journal:  Brain Sci       Date:  2022-05-06

Review 2.  Endocannabinoid-Mediated Neuromodulation in the Olfactory Bulb: Functional and Therapeutic Significance.

Authors:  Naina Bhatia-Dey; Thomas Heinbockel
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

3.  Ablation of tau causes an olfactory deficit in a murine model of Parkinson's disease.

Authors:  Leah C Beauchamp; Jacky Chan; Lin W Hung; Benjamin S Padman; Laura J Vella; Xiang M Liu; Bradley Coleman; Ashley I Bush; Michael Lazarou; Andrew F Hill; Laura Jacobson; Kevin J Barnham
Journal:  Acta Neuropathol Commun       Date:  2018-07-05       Impact factor: 7.801

4.  Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions.

Authors:  Marta Sidoryk-Wegrzynowicz; Yannick N Gerber; Miriam Ries; Magdalena Sastre; Aviva M Tolkovsky; Maria Grazia Spillantini
Journal:  Acta Neuropathol Commun       Date:  2017-11-29       Impact factor: 7.801

Review 5.  Olfactory dysfunction in aging and neurodegenerative diseases.

Authors:  Xiuli Dan; Noah Wechter; Samuel Gray; Joy G Mohanty; Deborah L Croteau; Vilhelm A Bohr
Journal:  Ageing Res Rev       Date:  2021-07-27       Impact factor: 11.788

6.  The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy.

Authors:  Alana N Vagnozzi; Phillip F Giannopoulos; Domenico Praticò
Journal:  Transl Psychiatry       Date:  2017-12-18       Impact factor: 6.222

7.  Functional Alterations in the Olfactory Neuronal Circuit Occur before Hippocampal Plasticity Deficits in the P301S Mouse Model of Tauopathy: Implications for Early Diagnosis and Translational Research in Alzheimer's Disease.

Authors:  Abdallah Ahnaou; Daniela Rodriguez-Manrique; Ria Biermans; Sofie Embrechts; Nikolay V Manyakov; Wilhelmus H Drinkenburg
Journal:  Int J Mol Sci       Date:  2020-07-30       Impact factor: 5.923

8.  Improved Sleep, Memory, and Cellular Pathological Features of Tauopathy, Including the NLRP3 Inflammasome, after Chronic Administration of Trazodone in rTg4510 Mice.

Authors:  Paula de Oliveira; Claire Cella; Nicolas Locker; Kiran K G Ravindran; Agampodi Mendis; Keith Wafford; Gary Gilmour; Derk-Jan Dijk; Raphaelle Winsky-Sommerer
Journal:  J Neurosci       Date:  2022-03-10       Impact factor: 6.709

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.